BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/5/2026 6:55:13 AM | Browse: 94 | Download: 319
 |
Received |
|
2025-07-16 02:34 |
|
Peer-Review Started |
|
2025-07-16 02:34 |
|
First Decision by Editorial Office Director |
|
2025-10-13 09:04 |
|
Return for Revision |
|
2025-10-13 14:01 |
|
Revised |
|
2025-10-13 16:07 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-12-15 02:38 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-16 01:58 |
|
Articles in Press |
|
2025-12-16 01:58 |
|
Edit the Manuscript by Language Editor |
|
2025-12-22 05:04 |
|
Typeset the Manuscript |
|
2025-12-30 05:47 |
|
Publish the Manuscript Online |
|
2026-01-05 06:55 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Discontinuation of advanced therapy in inflammatory bowel disease: Updated evidence, guidelines, and personalized decision-making one year later
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Salvatore Greco, Michele Campigotto and Nicolò Fabbri |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Salvatore Greco, MD, Department of Internal Medicine, Ospedale del Delta, AUSL Ferrara, Via valle Oppio 2, Lagosanto 44023, Ferrara, Italy. grcsvt@unife.it |
| Key Words |
Crohn’s disease; Ulcerative colitis; Inflammatory bowel disease; Biologic therapy; Discontinuation of therapy; Personalized medicine |
| Core Tip |
Discontinuation of advanced therapies in inflammatory bowel diseases remains a high-stakes decision, with relapse, immunogenicity, and long-term complications all weighing heavily. Despite updated international guidelines and emerging therapies, a personalized, closely monitored approach remains essential to ensure safe and effective treatment de-escalation in both Crohn’s disease and ulcerative colitis. |
| Publish Date |
2026-01-05 06:55 |
| Citation |
Greco S, Campigotto M, Fabbri N. Discontinuation of advanced therapy in inflammatory bowel disease: Updated evidence, guidelines, and personalized decision-making one year later. World J Clin Cases 2026; 14(1): 112021 |
| URL |
https://www.wjgnet.com/2307-8960/full/v14/i1/112021.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v14.i1.112021 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
